BE1028576A1 - Composition comprising at least one boswellic acid and/or at least one plant extract comprising at least one boswellic acid for topical use in the treatment of inflammatory skin diseases - Google Patents
Composition comprising at least one boswellic acid and/or at least one plant extract comprising at least one boswellic acid for topical use in the treatment of inflammatory skin diseases Download PDFInfo
- Publication number
- BE1028576A1 BE1028576A1 BE20216114A BE202106114A BE1028576A1 BE 1028576 A1 BE1028576 A1 BE 1028576A1 BE 20216114 A BE20216114 A BE 20216114A BE 202106114 A BE202106114 A BE 202106114A BE 1028576 A1 BE1028576 A1 BE 1028576A1
- Authority
- BE
- Belgium
- Prior art keywords
- boswellic acid
- composition
- acid
- plant extract
- use according
- Prior art date
Links
- NBGQZFQREPIKMG-UHFFFAOYSA-N 3beta-hydroxy-beta-boswellic acid Natural products C1CC(O)C(C)(C(O)=O)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C NBGQZFQREPIKMG-UHFFFAOYSA-N 0.000 title claims abstract description 44
- NBGQZFQREPIKMG-PONOSELZSA-N Boswellic acid Chemical compound C1C[C@@H](O)[C@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C NBGQZFQREPIKMG-PONOSELZSA-N 0.000 title claims abstract description 44
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 239000000419 plant extract Substances 0.000 title claims abstract description 24
- 230000000699 topical effect Effects 0.000 title claims abstract description 12
- 201000004624 Dermatitis Diseases 0.000 title abstract description 10
- 241000124008 Mammalia Species 0.000 claims abstract description 5
- 239000002253 acid Substances 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 150000002191 fatty alcohols Chemical class 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- -1 polysiloxanes Chemical class 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 235000013336 milk Nutrition 0.000 claims description 4
- 239000008267 milk Substances 0.000 claims description 4
- 210000004080 milk Anatomy 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- 235000019198 oils Nutrition 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 229920001296 polysiloxane Chemical class 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- 239000005639 Lauric acid Substances 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000005662 Paraffin oil Substances 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 239000010775 animal oil Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 claims description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 2
- 239000003974 emollient agent Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 239000003925 fat Substances 0.000 claims description 2
- 150000002194 fatty esters Chemical class 0.000 claims description 2
- 239000003349 gelling agent Substances 0.000 claims description 2
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- 239000003906 humectant Substances 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 235000014593 oils and fats Nutrition 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 229940068965 polysorbates Drugs 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 229920002545 silicone oil Chemical class 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 229960001295 tocopherol Drugs 0.000 claims description 2
- 229930003799 tocopherol Natural products 0.000 claims description 2
- 235000010384 tocopherol Nutrition 0.000 claims description 2
- 239000011732 tocopherol Substances 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 235000019871 vegetable fat Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 239000000341 volatile oil Substances 0.000 claims description 2
- 239000001993 wax Substances 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 2
- 239000004264 Petrolatum Substances 0.000 claims 1
- 235000019271 petrolatum Nutrition 0.000 claims 1
- 229940066842 petrolatum Drugs 0.000 claims 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 150000007513 acids Chemical class 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 240000007551 Boswellia serrata Species 0.000 description 6
- 239000003246 corticosteroid Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 235000012035 Boswellia serrata Nutrition 0.000 description 4
- 229960001334 corticosteroids Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
- 208000029422 Hypernatremia Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 229920005479 Lucite® Polymers 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 208000031439 Striae Distensae Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- NENOAJSZZPODGJ-OIMNJJJWSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] octanoate Chemical group CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NENOAJSZZPODGJ-OIMNJJJWSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 239000005550 inflammation mediator Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 208000005005 intertrigo Diseases 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 230000007943 positive regulation of appetite Effects 0.000 description 1
- 230000005004 positive regulation of lymphocyte proliferation Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000003236 psychic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention porte sur une composition comprenant au moins un acide boswellique et/ou au moins un extrait végétal comprenant au moins un acide boswellique pour utilisation topique dans le traitement des maladies inflammatoires de la peau chez un mammifère, en particulier chez un être humain.The present invention relates to a composition comprising at least one boswellic acid and/or at least one plant extract comprising at least one boswellic acid for topical use in the treatment of inflammatory skin diseases in a mammal, in particular in a human being.
Description
+ BE2021/6114 Composition comprenant au moins un acide boswellique et/ou au moins un extrait vegetal comprenant au moins un acide boswellique pour utilisation topique dans le traitement des maladies inflammatoires de la peau La presente invention porte sur une composition comprenant au moins un acide boswellique et/ou au moins un extrait végétal comprenant au moins un acide boswellique pour utilisation topique dans le traitement des maladies inflammatoires de la peau chez un mammifère, en particulier chez un être humain.+ BE2021/6114 Composition comprising at least one boswellic acid and/or at least one plant extract comprising at least one boswellic acid for topical use in the treatment of inflammatory skin diseases The present invention relates to a composition comprising at least one boswellic acid and/or at least one plant extract comprising at least one boswellic acid for topical use in the treatment of inflammatory skin diseases in a mammal, in particular in a human being.
Les maladies inflammatoires de la peau sont nombreuses et peuvent toucher toutes les parties du corps. Aujourd’hui, de nombreuses pathologies dermatologiques inflammatoires dysimmunitaires ou prolifératives sont traitées à l’aide de (dermo-)corticoïdes dont l’utilisation est notamment classique pour la prise en charge de dermatoses comme le psoriasis, la dermatite atopique ou l’eczéma.Inflammatory skin diseases are numerous and can affect all parts of the body. Today, many inflammatory, dysimmune or proliferative dermatological pathologies are treated with (dermo-)corticoids, the use of which is particularly conventional for the management of dermatoses such as psoriasis, atopic dermatitis or eczema.
Toutefois, mêmes si les (dermo-)corticoïdes exercent une puissante action anti-inflammatoire, ils sont également à l’origine de nombreux effets secondaires dont la fréquence et l'importance dépendent de plusieurs facteurs comme la posologie, la durée du traitement, la nature du corticoïde, la sensibilité individuelle aux corticoïdes et l’état de santé du patient.However, even if (dermo-)corticosteroids exert a powerful anti-inflammatory action, they are also the cause of many side effects, the frequency and importance of which depend on several factors such as the dosage, the duration of the treatment, the nature of the corticosteroid, individual sensitivity to corticosteroids and the patient's state of health.
Les principaux effets secondaires observés avec les corticoïdes sont les suivants : une prise de poids localisée au niveau du visage et du tronc, des troubles sanguins (baisse du taux de potassium), une rétention d’eau et de sel (entraînant des œdèmes et une augmentation de la tension artérielle), une stimulation de l’appétit, une intolérance au glucose (pouvant révéler ou accentuer un diabète), une augmentation des taux sanguins de lipides, des troubles cutanés (fragilité de la peau et des capillaires, acné, vergetures, problèmes de cicatrisation), une faiblesse musculaire (notamment au niveau des jambes), une perte de masse osseuse, un retard de croissance chez l'enfant, des troubles digestifs (acidité gastrique), une immunodépression, des troubles du sommeil et des troubles psychiques (dépression, délire, hallucinations) et des complications oculaires (de type cataracte voire de glaucome chez certaines personnes prédisposées).The main side effects observed with corticosteroids are as follows: localized weight gain in the face and trunk, blood disorders (lowered potassium levels), water and salt retention (resulting in edema and increase in blood pressure), stimulation of appetite, glucose intolerance (which may reveal or accentuate diabetes), increased blood lipid levels, skin disorders (fragility of the skin and capillaries, acne, stretch marks , healing problems), muscle weakness (especially in the legs), loss of bone mass, growth retardation in children, digestive disorders (stomach acidity), immunosuppression, sleep disorders and psychic (depression, delirium, hallucinations) and ocular complications (such as cataracts or even glaucoma in certain predisposed people).
A ce jour, il existe donc un réel besoin de procurer une composition pour traiter les inflammations de la peau qui permette de s'affranchir au moins en partie des effets secondaires mentionnés ci-dessus et observés lors d’un traitement reposant sur une utilisation de (dermo-)corticoïdes.To date, there is therefore a real need to provide a composition for treating inflammation of the skin which makes it possible to overcome, at least in part, the side effects mentioned above and observed during a treatment based on the use of (dermo-)corticosteroids.
Pour adresser au moins en partie ces problèmes, il est prévu, suivant l'invention, une composition comprenant au moins un acide boswellique et/ou au moins un extrait végétal comprenant au moins un acide boswellique pour utilisation topique dans le traitement des maladies inflammatoires de la peau chez un mammifère, en particulier chez un être humain.To address these problems at least in part, provision is made, according to the invention, for a composition comprising at least one boswellic acid and/or at least one plant extract comprising at least one boswellic acid for topical use in the treatment of inflammatory diseases of the skin in a mammal, in particular in a human being.
Par les termes « maladies inflammatoires de la peau », il est entendu, au sens de la présente invention, tout type d’inflammation du derme, de l’épiderme et/ou de l’'hypoderme.By the terms “inflammatory skin diseases”, it is understood, within the meaning of the present invention, any type of inflammation of the dermis, epidermis and/or hypodermis.
Par les termes « utilisation topique », il est entendu, au sens de la présente invention, une utilisation à usage local, en particulier une utilisation à usage local de telle sorte que le principe actif (c’est-à-dire au moins un acide boswellique) ne passe pas dans le système circulatoire (ou dans le sang). Plus particulièrement, une « utilisation topique » au sens de la présente invention est une utilisation sur la peau ou sur une muqueuse de telle sorte que la composition ainsi appliquée de façon topique agisse uniquement à l'endroit où elle est appliquée sur la peau ou sur une muqueuse. Il s’agit donc d’une application topique cutanée et/ou au niveau d’une muqueuse.By the terms "topical use", it is understood, within the meaning of the present invention, a use for local use, in particular a use for local use such that the active principle (that is to say at least one boswellic acid) does not pass into the circulatory system (or blood). More particularly, a "topical use" within the meaning of the present invention is a use on the skin or on a mucous membrane such that the composition thus applied topically acts only at the place where it is applied to the skin or on a mucous membrane. It is therefore a topical application to the skin and/or to the mucosa.
Une composition selon l'invention permet donc notamment de réaliser un traitement dermatologique des maladies inflammatoires de la peau. Parmi les maladies inflammatoires de la peau pouvant être traitées avec une telle composition suivant l'invention, on peut mentionner : l’'eczéma, l'eczéma de contact, le psoriasis, la cellulite, la lucite, l’urticaire, une inflammation due à une piqûre, les dermatites, les dermatites atopiques, l’hypodermite, l'intertrigo, … Cette liste est non exhaustive.A composition according to the invention therefore makes it possible in particular to carry out a dermatological treatment of inflammatory diseases of the skin. Among the inflammatory skin diseases that can be treated with such a composition according to the invention, mention may be made of: eczema, contact eczema, psoriasis, cellulitis, lucite, urticaria, inflammation due to to a bite, dermatitis, atopic dermatitis, hypodermatitis, intertrigo, etc. This list is not exhaustive.
Les acides boswelliques sont essentiellement extrait du végétal Boswellia serrata et présentent plusieurs propriétés dont notamment les suivantes : inhibition de la production de médiateurs de l’inflammation (5- lipoxygénase et leucotriènes), inhibition de l'activation du NFkappaB, diminution des interleukines (IL-1, IL-2, IL-4, IL-6 et l'interféron-gamma), action sur la production d'anticorps, action sur l’immunité à médiation cellulaire, immunomodulation, stimulation de la prolifération lymphocytaire, induction de l'apoptose de certaines cellules cancéreuses en inhibant la topoisomérase |, amélioration de l'efficacité des chimiothérapies, inhibition de l'expression du NF- kappaB et amélioration des symptômes de la maladie de Crohn.Boswellic acids are essentially extracted from the Boswellia serrata plant and have several properties, including the following: inhibition of the production of inflammation mediators (5-lipoxygenase and leukotrienes), inhibition of NFkappaB activation, reduction of interleukins (IL -1, IL-2, IL-4, IL-6 and interferon-gamma), action on antibody production, action on cell-mediated immunity, immunomodulation, stimulation of lymphocyte proliferation, induction of apoptosis of certain cancer cells by inhibiting topoisomerase |, improvement in the efficacy of chemotherapy, inhibition of the expression of NF-kappaB and improvement in the symptoms of Crohn's disease.
Dans le cadre de la présente invention, il a été mis en évidence qu'un usage topique d’une composition comprenant au moins un acide boswellique et/ou au moins un extrait végétal comprenant au moins un acide boswellique permet de traiter efficacement et sans effets secondaires (tels que ceux mentionnés plus haut) les maladies inflammatoires de la peau chez un mammifère, en particulier chez un être humain.In the context of the present invention, it has been demonstrated that topical use of a composition comprising at least one boswellic acid and/or at least one plant extract comprising at least one boswellic acid makes it possible to treat effectively and without effects secondary (such as those mentioned above) inflammatory diseases of the skin in a mammal, in particular in a human being.
De préférence, dans une composition suivant l'invention, ledit au moins un acide boswellique et/ou ledit au moins un extrait végétal comprenant au moins un acide boswellique est présent à raison de 0,5% à 15% en poids par rapport au poids total de la composition.Preferably, in a composition according to the invention, said at least one boswellic acid and/or said at least one plant extract comprising at least one boswellic acid is present in a proportion of 0.5% to 15% by weight relative to the weight composition total.
Selon l'invention, lorsque la composition comprend au moins un extrait végétal comprenant au moins un acide boswellique, cet extrait végétal est standarisé entre 10 et 90% en acides boswelliques.According to the invention, when the composition comprises at least one plant extract comprising at least one boswellic acid, this plant extract is standardized between 10 and 90% in boswellic acids.
De préférence, selon l'invention, ledit au moins un extrait végétal est un extrait du végétal Boswellia serrata standardisé entre 10 et 90% en acides boswelliques, de préférence standardisé à 65% en acides boswelliques.Preferably, according to the invention, said at least one plant extract is an extract of the plant Boswellia serrata standardized between 10 and 90% in boswellic acids, preferably standardized at 65% in boswellic acids.
Avantageusement, la composition suivant l'invention comprend en outre au moins un corps gras et/ou de l’eau en tant qu’excipient.Advantageously, the composition according to the invention also comprises at least one fatty substance and/or water as an excipient.
Préférentiellement, dans une composition suivant l'invention, ledit au moins un corps gras et/ou de l’eau en tant qu’excipient est présent à raison de 10% à 90% en poids par rapport au poids total de la composition.Preferably, in a composition according to the invention, said at least one fatty substance and/or water as excipient is present in a proportion of 10% to 90% by weight relative to the total weight of the composition.
De préférence, dans une composition suivant l'invention, ledit au moins un corps gras en tant qu'excipient est choisi parmi l'huile de paraffine, l'huile de vaseline, les huiles et les graisses végétales, les huiles et les graisses animales, les glycérides, les cires, les polyalkylsiloxanes, les esters d'acide lanolique, d'acide oléique, d'acide laurique, d'acide stéarique, les esters gras, les acides gras supérieurs à au moins 12 atomes de carbone, les alcools gras supérieurs à au moins 12 atomes de carbone, les huiles siliconées, les polysiloxanes modifiés par des acides gras, des alcools gras ou des polyoxyalkylènes, les silicones fluorées, les huiles perfluorées et les huiles volatiles.Preferably, in a composition according to the invention, said at least one fatty substance as excipient is chosen from paraffin oil, vaseline oil, vegetable oils and fats, animal oils and fats , glycerides, waxes, polyalkylsiloxanes, esters of lanolic acid, oleic acid, lauric acid, stearic acid, fatty esters, fatty acids with at least 12 carbon atoms, alcohols fatty acids with at least 12 carbon atoms, silicone oils, polysiloxanes modified with fatty acids, fatty alcohols or polyoxyalkylenes, fluorinated silicones, perfluorinated oils and volatile oils.
Préférentiellement, la composition suivant l'invention comprend du glycérol (glycérine). Le glycérol est un corps gras permettant notamment d’hydrater et de réparer les peaux sèches.Preferably, the composition according to the invention comprises glycerol (glycerine). Glycerol is a fatty substance that notably helps moisturize and repair dry skin.
Avantageusement, la composition suivant l'invention comprend en outre au moins un agent émulsifiant choisi parmi les esters de sorbitan, les monoglycérides, les alcools gras, les alcools gras sulfatés, les polysorbates et les esters d'acides gras.Advantageously, the composition according to the invention also comprises at least one emulsifying agent chosen from sorbitan esters, monoglycerides, fatty alcohols, sulphated fatty alcohols, polysorbates and fatty acid esters.
Préférentiellement, ledit au moins un agent émulsifiant est le sorbitan caprylate ou le glycéryl stéarate (stéarate de glycérol).Preferably, said at least one emulsifying agent is sorbitan caprylate or glyceryl stearate (glycerol stearate).
Avantageusement, la composition suivant l'invention comprend en outre au moins un agent de liaison / agent liant, par exemple de la maltodextrine.Advantageously, the composition according to the invention also comprises at least one binding agent/binding agent, for example maltodextrin.
De préférence, la composition suivant l'invention comprend en outre au moins un agent gélifiant / agent épaississant, par exemple de la gomme de xanthane.Preferably, the composition according to the invention also comprises at least one gelling agent/thickening agent, for example xanthan gum.
Avantageusement, la composition suivant l'invention comprend en outre au moins un agent conservateur, par exemple du benzoate de sodium ou de l'acide benzoïque.Advantageously, the composition according to the invention also comprises at least one preservative, for example sodium benzoate or benzoic acid.
De préférence, la composition suivant l'invention comprend en outre au moins un agent humectant / agent émollient, par exemple du propanédiol.Preferably, the composition according to the invention also comprises at least one humectant/emollient agent, for example propanediol.
Avantageusement, la composition suivant l'invention comprend en outre au moins un agent antioxydant, par exemple du tocophérol.Advantageously, the composition according to the invention also comprises at least one antioxidant agent, for example tocopherol.
De préférence, la composition suivant l'invention comprend en outre au moins un agent régulateur de pH, par exemple de l’hydroxyde de sodium.Preferably, the composition according to the invention further comprises at least one pH regulating agent, for example sodium hydroxide.
Préférentiellement, la composition suivant l'invention se présente sous la forme d’une pommade, d’un onguent, d’une crème, d’un lait ou encore sous toute forme permettant une application topique.Preferably, the composition according to the invention is in the form of an ointment, an ointment, a cream, a milk or even in any form allowing topical application.
D’autres caractéristiques, détails et avantages de l'invention ressortiront de l'exemple donné ci-après, à titre non limitatif.Other characteristics, details and advantages of the invention will emerge from the example given below, without limitation.
Exemples Exemple 1 5 Le Tableau 1 ci-dessous est un exemple d’une composition selon l'invention se présentant sous forme d’une crème.Examples Example 1 Table 1 below is an example of a composition according to the invention in the form of a cream.
Cette crème a été préparée par incorporation d’un extrait sous forme de poudre de Boswellia serrata standardisé à 65% d’acides boswelliques dans un corps gras en tant qu’excipient avec de l’eau.This cream was prepared by incorporating an extract in powder form of Boswellia serrata standardized to 65% boswellic acids in a fatty substance as an excipient with water.
Les pourcentages mentionnés dans le Tableau 1 ci-dessous sont des pourcentages en poids.The percentages mentioned in Table 1 below are percentages by weight.
Tableau 1 Extrait de Boswellia serrata standardisé à 5 65% d'acides boswelliques Exemple 2 Le Tableau 2 ci-dessous est un exemple d’une composition selon l'invention se présentant sous forme d’un lait.Table 1 Extract of Boswellia serrata standardized to 565% boswellic acids Example 2 Table 2 below is an example of a composition according to the invention in the form of a milk.
Ce lait a été préparé par incorporation d’un extrait sous forme de poudre de Boswellia serrata standardisé à 65% d'acides boswelliques dans un corps gras en tant qu’excipient avec de l’eau.This milk was prepared by incorporating an extract in powder form of Boswellia serrata standardized to 65% boswellic acids in a fatty substance as an excipient with water.
Les pourcentages mentionnés dans le Tableau 2 ci-dessous sont des pourcentages en poids.The percentages mentioned in Table 2 below are percentages by weight.
© BE2021/6114 Tableau 2 Extrait de Boswellia serrata standardisé à 5 Ee La présente invention a été décrite en relation avec des modes de réalisations spécifiques, qui ont une valeur purement illustrative et ne doivent pas être considérés comme limitatifs. D'une manière générale, il apparaîtra évident pour l’homme du métier que la présente invention n’est pas limitée aux exemples illustrés et/ou décrits ci-dessus.© BE2021/6114 Table 2 Extract of Boswellia serrata standardized to 5 Ee The present invention has been described in relation to specific embodiments, which have a purely illustrative value and should not be considered as limiting. In general, it will appear obvious to those skilled in the art that the present invention is not limited to the examples illustrated and/or described above.
L’usage des verbes « comprendre », « inclure », « comporter », ou toute autre variante, ainsi que leurs conjugaisons, ne peut en aucune façon exclure la présence d’éléments autres que ceux mentionnés.The use of the verbs "understand", "include", "compose", or any other variant, as well as their conjugations, can in no way exclude the presence of elements other than those mentioned.
L’usage de l’article indéfini « un », «une », ou de l’article défini « le », «la» OU « l” », pour introduire un élément n'exclut pas la présence d’une pluralité de ces éléments.The use of the indefinite article “un”, “une”, or of the definite article “le”, “la” OR “l””, to introduce an element does not exclude the presence of a plurality of these elements.
Claims (13)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BE20216114A BE1028576B1 (en) | 2021-12-30 | 2021-12-30 | Composition comprising at least one boswellic acid and/or at least one plant extract comprising at least one boswellic acid for topical use in the treatment of inflammatory skin diseases |
| FR2213948A FR3130555B3 (en) | 2021-12-30 | 2022-12-20 | Composition comprising at least one boswellic acid and/or at least one plant extract comprising at least one boswellic acid for topical use in the treatment of inflammatory skin diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BE20216114A BE1028576B1 (en) | 2021-12-30 | 2021-12-30 | Composition comprising at least one boswellic acid and/or at least one plant extract comprising at least one boswellic acid for topical use in the treatment of inflammatory skin diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BE1028576A1 true BE1028576A1 (en) | 2022-03-23 |
| BE1028576B1 BE1028576B1 (en) | 2023-08-17 |
Family
ID=79425527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE20216114A BE1028576B1 (en) | 2021-12-30 | 2021-12-30 | Composition comprising at least one boswellic acid and/or at least one plant extract comprising at least one boswellic acid for topical use in the treatment of inflammatory skin diseases |
Country Status (2)
| Country | Link |
|---|---|
| BE (1) | BE1028576B1 (en) |
| FR (1) | FR3130555B3 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE1029955B1 (en) * | 2022-05-16 | 2023-06-16 | Dyna S A R L | Composition comprising at least one boswellic acid and/or at least one plant extract comprising at least one boswellic acid for topical use in the treatment of skin aging |
| BE1030237B1 (en) * | 2022-06-21 | 2023-08-25 | Dyna S A R L | Composition comprising at least one boswellic acid and/or at least one plant extract comprising at least one boswellic acid for topical use in the treatment of cellulite |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7582314B2 (en) * | 2003-12-03 | 2009-09-01 | Sami Labs Ltd. | Compositions and methods for the management of hyperproliferative dermatological conditions |
| GB0413954D0 (en) * | 2004-06-22 | 2004-07-28 | Altunkaya Ali | Compositions for topical treatment |
| PL2444081T3 (en) * | 2010-10-19 | 2015-09-30 | Parenteral A S | A composition for the treatment of inflammatory diseases comprising boswellic acids and cannabidiol |
| US20210093724A1 (en) * | 2019-09-30 | 2021-04-01 | Concept Matrix Solutions | Topical anti-acne composition |
-
2021
- 2021-12-30 BE BE20216114A patent/BE1028576B1/en active IP Right Grant
-
2022
- 2022-12-20 FR FR2213948A patent/FR3130555B3/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE1029955B1 (en) * | 2022-05-16 | 2023-06-16 | Dyna S A R L | Composition comprising at least one boswellic acid and/or at least one plant extract comprising at least one boswellic acid for topical use in the treatment of skin aging |
| BE1030237B1 (en) * | 2022-06-21 | 2023-08-25 | Dyna S A R L | Composition comprising at least one boswellic acid and/or at least one plant extract comprising at least one boswellic acid for topical use in the treatment of cellulite |
Also Published As
| Publication number | Publication date |
|---|---|
| FR3130555A3 (en) | 2023-06-23 |
| BE1028576B1 (en) | 2023-08-17 |
| FR3130555B3 (en) | 2024-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR3130555A3 (en) | Composition comprising at least one boswellic acid and/or at least one plant extract comprising at least one boswellic acid for topical use in the treatment of inflammatory skin diseases | |
| EP0892642B1 (en) | Use in a composition of an extract of at least one labiate of the genus rosmarinarus, cultured in vitro | |
| EP0278809B1 (en) | Cosmetic or dermatologic compositions containing a silybum marianum fruit extract rich in sylimarin together with essential fatty acids | |
| EP1758588B1 (en) | Pharmaceutical composition comprising an ointment and two solubilized active principles | |
| FR2694692A1 (en) | Cosmetic compsn for skin nutrition - contains essential fatty acids, vitamin(s) and chelated trace and major elements | |
| EP1786384A1 (en) | Use of at least one conjugated triene-containing fatty acid for preparing a medicine for treating inflammation | |
| CH669727A5 (en) | ||
| FR2822381A1 (en) | New superoxide dismutase compositions, used for e.g. prevention and treatment allergies, inflammatory disorders, and degenerative disorders, comprise Cucumis melo extract and a liposoluble fatty material | |
| FR2490492A1 (en) | Compsns. for treating cellulitis - contg. xanthine base and seaweed extract | |
| WO2014181267A1 (en) | Use of petroselinic acid to fight against aesthetic disorders of the body figure | |
| FR2591109A1 (en) | DRUG COMPOSITION BASED ON NATURAL OIL OF VEGETABLE ORIGIN FOR USE IN THE TREATMENT OF HERPES. | |
| CA3188531A1 (en) | Topical compositions, process of large-scale manufacture, and method of use | |
| EP1002524B1 (en) | Skin antiageing composition | |
| EP1019017B1 (en) | Association of phenol derivatives with extract of iridaceae family for lightening the skin and superficial body growth and composition containing same | |
| FR2591104A1 (en) | Cosmetic product based on natural oil of vegetable origin | |
| FR3130587A3 (en) | Composition comprising at least one boswellic acid and/or at least one plant extract comprising at least one boswellic acid for topical use in the treatment of skin aging | |
| FR2633516A1 (en) | Cosmetic composition for the treatment of dehydrated sensitive skins | |
| FR2649011A1 (en) | MEDICINAL PRODUCT FOR REVASCULARIZATION OF TISSUES | |
| FR2880538A1 (en) | Composition, useful in an anti-inflammatory and moisturizing for skin, comprises fish oil and phospholipids | |
| FR3131196A1 (en) | Composition for the treatment and/or prevention of the reappearance of pink stretch marks | |
| FR2681783A1 (en) | Mixture of vegetable oils which is rich in essential fatty acids and its use in cosmetic compositions | |
| FR2876908A1 (en) | Use of chaulmoogra oil, or its components, for treatment or prevention of excess fat and cellulitis, acts by inducing lipolysis | |
| WO2020083694A1 (en) | Dermatological composition intended for the prevention and/or treatment of mastodynia | |
| FR3047667B1 (en) | NOVEL COSMETIC OR DERMATOLOGICAL COMPOSITION FOR THE TREATMENT OF REDNESS | |
| WO2023002119A1 (en) | Use of a lipid extract from skeletonema algae for promoting and/or stimulating skin repair |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Effective date: 20230817 |
|
| PD | Change of ownership |
Owner name: DYNA SPECIALIST SRL; BE Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: DYNA + S.A.R.L. Effective date: 20231213 |